• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Patterson Companies Inc. (Amendment)

    2/14/23 12:37:55 PM ET
    $PDCO
    Medical Specialities
    Health Care
    Get the next $PDCO alert in real time by email
    SC 13G/A 1 pdco13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6) PATTERSON COS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 703395103 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 1,697,422 6. Shared Voting Power* 0 7. Sole Dispositive Power* 4,366,620 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 4,366,620 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 4.4% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: PATTERSON COS INC Item 1(b) Address of Issuer's Principal Executive Offices: 1031 MENDOTA HEIGHTS RD, ST PAUL, MINNESOTA 55120-1401 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates) Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 703395103 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class This statement is being filed to report the fact that, as of the date of this report, the reporting person(s) has (have) ceased to be the beneficial owner of more than five percent of the class of securities. Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 14, 2023 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2022
    Get the next $PDCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PDCO

    DatePrice TargetRatingAnalyst
    12/4/2024$23.00Neutral
    Mizuho
    2/29/2024$34.00 → $28.00Overweight → Neutral
    Piper Sandler
    2/26/2024$36.00Outperform
    Leerink Partners
    5/13/2022$36.00Outperform
    Credit Suisse
    3/3/2022$30.00 → $32.00Equal-Weight
    Morgan Stanley
    1/31/2022$30.00Equal-Weight
    Morgan Stanley
    10/1/2021$38.00Outperform
    Credit Suisse
    More analyst ratings

    $PDCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Patterson Companies with a new price target

      Mizuho initiated coverage of Patterson Companies with a rating of Neutral and set a new price target of $23.00

      12/4/24 7:46:30 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • Patterson Companies downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Patterson Companies from Overweight to Neutral and set a new price target of $28.00 from $34.00 previously

      2/29/24 6:36:04 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • Leerink Partners initiated coverage on Patterson Companies with a new price target

      Leerink Partners initiated coverage of Patterson Companies with a rating of Outperform and set a new price target of $36.00

      2/26/24 8:10:56 AM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tomczik Pamela J returned 7,820 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - PATTERSON COMPANIES, INC. (0000891024) (Issuer)

      4/17/25 2:15:41 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • Director Schrimsher Neil A returned 48,788 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - PATTERSON COMPANIES, INC. (0000891024) (Issuer)

      4/17/25 2:08:45 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • Director Mckoy Philip returned 18,114 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - PATTERSON COMPANIES, INC. (0000891024) (Issuer)

      4/17/25 2:06:32 PM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sterling Infrastructure Set to Join S&P SmallCap 600

      NEW YORK, April 14, 2025 /PRNewswire/ -- Sterling Infrastructure Inc. (NASD: STRL) will replace Patterson Companies Inc. (NASD: PDCO) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, April 17. Patient Square Capital is acquiring Patterson Companies in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector April 17, 2025 S&P SmallCap 600 Addition Sterling Infrastructure STRL Industrials April 17, 2025 S&P SmallCap 600 Deletion Patterson Companies PDCO Health Care Fo

      4/14/25 6:43:00 PM ET
      $PDCO
      $SPGI
      $STRL
      Medical Specialities
      Health Care
      Finance: Consumer Services
      Finance
    • Patterson Companies, Inc. Shareholders Approve Acquisition by Patient Square Capital

      Patterson Companies, Inc. (NASDAQ:PDCO), a value-added specialty distributor serving the U.S. and Canadian dental supply markets and the U.S., Canadian and U.K. animal health supply markets, today announced that its shareholders approved at a special meeting the acquisition of Patterson by Patient Square Capital, a dedicated health care investment firm. Don Zurbay, Patterson's President and Chief Executive Officer, said, "I would like to express my gratitude to the Patterson shareholders for their support today, and throughout this transaction process. The Patterson team is excited about this partnership with Patient Square Capital and beginning our next chapter as a private company. We be

      4/1/25 1:00:00 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • Patterson Companies Reports Fiscal 2025 Third Quarter Operating Results

      Third quarter reported net sales decreased 2.7 percent year-over-year to $1.57 billion, and internal sales decreased 2.4 percent. Delivered third quarter GAAP earnings of $0.35 per diluted share and adjusted earnings1 of $0.43 per diluted share; both GAAP and adjusted earnings1 were negatively impacted by the cybersecurity attack on Change Healthcare compared to the prior year. Returned $119.2 million to shareholders in the form of cash dividends and share repurchases through the first nine months of fiscal 2025. Patterson Companies, Inc. (NASDAQ:PDCO) today reported operating results for its fiscal 2025 third quarter ended January 25, 2025. "As we continue to progress toward cl

      2/26/25 4:30:00 PM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Patterson Companies Inc.

      15-12G - PATTERSON COMPANIES, INC. (0000891024) (Filer)

      4/28/25 10:30:38 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • SEC Form 8-K filed by Patterson Companies Inc.

      8-K - PATTERSON COMPANIES, INC. (0000891024) (Filer)

      4/22/25 9:00:17 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Patterson Companies Inc.

      S-8 POS - PATTERSON COMPANIES, INC. (0000891024) (Filer)

      4/17/25 9:23:38 AM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    Leadership Updates

    Live Leadership Updates

    See more
    • Sterling Infrastructure Set to Join S&P SmallCap 600

      NEW YORK, April 14, 2025 /PRNewswire/ -- Sterling Infrastructure Inc. (NASD: STRL) will replace Patterson Companies Inc. (NASD: PDCO) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, April 17. Patient Square Capital is acquiring Patterson Companies in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector April 17, 2025 S&P SmallCap 600 Addition Sterling Infrastructure STRL Industrials April 17, 2025 S&P SmallCap 600 Deletion Patterson Companies PDCO Health Care Fo

      4/14/25 6:43:00 PM ET
      $PDCO
      $SPGI
      $STRL
      Medical Specialities
      Health Care
      Finance: Consumer Services
      Finance
    • Patterson Companies Announces Dental Leadership Appointment

      Kristin Dietzler Named Dental President Patterson Companies Inc. (NASDAQ:PDCO) announced the appointment of Kristin Dietzler as Patterson Dental's North American president. Dietzler brings extensive expertise in adjacent healthcare companies with a proven track record of success in optimizing results. She will report to Kevin Pohlman, chief operating officer of Patterson Companies, and she will be a member of the company's executive leadership team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241023782217/en/Kristin Dietzler Named Patterson Dental President (Photo: Business Wire) Dietzler joins Patterson Dental with nearly 30

      10/23/24 6:00:00 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • Patterson Companies Announces Dental Leadership Transition

      Patterson Companies, Inc. (NASDAQ:PDCO) today announced that it has initiated a search for a new leader for its Dental segment. Tim Rogan, who has served as President of Patterson Dental since 2021, has stepped down from his role, effective immediately, and agreed to serve as an advisor to the Company in the short term to facilitate a smooth transition. The Dental segment will continue to report to Chief Operating Officer, Kevin Pohlman. "Our dental business has made significant progress to further enhance our value proposition and differentiate Patterson as the partner of choice for our customers. After careful consideration, we determined that a leadership transition will best position

      5/10/24 7:00:00 AM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    Financials

    Live finance-specific insights

    See more
    • Patterson Companies Reports Fiscal 2025 Third Quarter Operating Results

      Third quarter reported net sales decreased 2.7 percent year-over-year to $1.57 billion, and internal sales decreased 2.4 percent. Delivered third quarter GAAP earnings of $0.35 per diluted share and adjusted earnings1 of $0.43 per diluted share; both GAAP and adjusted earnings1 were negatively impacted by the cybersecurity attack on Change Healthcare compared to the prior year. Returned $119.2 million to shareholders in the form of cash dividends and share repurchases through the first nine months of fiscal 2025. Patterson Companies, Inc. (NASDAQ:PDCO) today reported operating results for its fiscal 2025 third quarter ended January 25, 2025. "As we continue to progress toward cl

      2/26/25 4:30:00 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • Patterson Companies Reports Fiscal 2025 Second Quarter Operating Results

      Second quarter reported net sales increased 1.3 percent year-over-year to $1.67 billion, and internal sales increased 0.6 percent. Delivered second quarter GAAP earnings of $0.30 per diluted share and adjusted earnings1 of $0.47 per diluted share; both GAAP and adjusted earnings1 were negatively impacted by the cybersecurity attack on Change Healthcare compared to the prior year. Returned $96.2 million to shareholders in the form of cash dividends and share repurchases through the first six months of fiscal 2025. Revises fiscal 2025 GAAP earnings guidance range to $1.83 to $1.93 per diluted share and adjusted earnings1 guidance range to $2.25 to $2.35 per diluted share. Company

      12/5/24 7:00:00 AM ET
      $PDCO
      Medical Specialities
      Health Care
    • Patterson Companies Fiscal 2025 Second Quarter Conference Call Scheduled for Thursday, December 5, 2024

      Patterson Companies (NASDAQ:PDCO) today announced that it will hold its fiscal 2025 second-quarter conference call on Thursday, December 5, 2024, at 7:30 a.m. CT (8:30 a.m. ET). The company's earnings release will be issued that morning before the market opens. To access the live webcast, go to the investor relations section of the company's website, www.PattersonCompanies.com. An audio replay of the fiscal 2025 second-quarter conference call will also be available for one week. To access the audio replay, please pre-register at https://registrations.events/direct/Q4I672812531 to receive a unique access code to access and listen to the audio playback. About Patterson Companies Inc. Pa

      11/27/24 7:19:00 PM ET
      $PDCO
      Medical Specialities
      Health Care

    $PDCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Patterson Companies Inc. (Amendment)

      SC 13G/A - PATTERSON COMPANIES, INC. (0000891024) (Subject)

      2/13/24 5:12:03 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Patterson Companies Inc. (Amendment)

      SC 13G/A - PATTERSON COMPANIES, INC. (0000891024) (Subject)

      12/8/23 4:16:31 PM ET
      $PDCO
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Patterson Companies Inc. (Amendment)

      SC 13G/A - PATTERSON COMPANIES, INC. (0000891024) (Subject)

      2/14/23 12:37:55 PM ET
      $PDCO
      Medical Specialities
      Health Care